Protonen- versus Photonenbestrahlung beim Oropharynxkarzinom
Alexander Rühle et al.
The article examines the differences between proton and photon radiotherapy in the treatment of oropharyngeal carcinoma, focusing on treatment effectiveness, toxicity, and quality of life. Oropharyngeal cancer patients often require high radiation doses in anatomically sensitive regions, making the reduction of damage to surrounding healthy tissues an important therapeutic goal. The article discusses whether proton therapy, due to its physical dose distribution advantages, can improve outcomes compared with conventional photon-based radiotherapy.
The development section of the study highlights the physical and clinical characteristics of both techniques. Photon radiotherapy, particularly intensity-modulated radiotherapy (IMRT), is widely established and achieves effective tumor control. However, photons deposit radiation along their entire path, exposing normal tissues such as salivary glands, swallowing muscles, and the oral cavity to unnecessary doses. Proton therapy, by contrast, uses the Bragg peak effect, allowing most of the radiation energy to be released directly within the tumor while minimizing exit dose. Clinical comparisons presented in the article indicate that proton therapy can significantly reduce acute and long-term side effects, including xerostomia, dysphagia, mucositis, and feeding-tube dependency. Several studies also suggest improvements in patient-reported quality of life and lower rates of treatment-related complications.
In conclusion, the article argues that proton therapy represents a promising alternative for selected patients with oropharyngeal carcinoma, especially younger patients and those with HPV-associated tumors who have long life expectancy after treatment. Although tumor control appears comparable between proton and photon therapy, the reduced toxicity profile of proton treatment may provide substantial long-term clinical benefits. The authors emphasize, however, that additional prospective randomized trials are still required to confirm these advantages and to justify the higher costs and limited availability of proton therapy.
Published by Strahlentherapie und Onkologie
